FrancophonIA/ELRC3.0 huggingface dataset:
English: 2-day treatment pack containing: 2 x 80 mg hard capsule 5 x 1 hard capsule
Croatian: Pakiranje za dvodnevno liječenje koje sadrži: 2 x 80 mg tvrde kapsule 5 x 1 tvrda kapsula
English: The recommended oral dose of EMEND is a single 40 mg dose within 3 hours prior to induction of anaesthesia.
Croatian: Preporučena peroralna doza lijeka EMEND je jedna doza od 40 mg unutar 3 sata prije uvođenja u anesteziju.
English: - If you have any further questions, ask the doctor, pharmacist, or nurse.
Croatian: - Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili medicinskoj sestri.
English: § - Overall phase Complete response = No vomiting or retching or dry heaves and no use of rescue medication.
Croatian: § - cijelo razdoblje Potpuni odgovor = bez povraćanja ili dizanja želuca ili nadražaja na povraćanje i bez primjene dodatnih lijekova za olakšanje simptoma.
English: Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Croatian: Obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli bilo koje druge lijekove.
English: EMEND contains sucrose and lactose
Croatian: EMEND sadrži saharozu i laktozu
English: EMEND contains sucrose
Croatian: EMEND sadrži saharozu
English: Administration of body surface area adjusted doses to patients 6 months to less than 12 years achieved a mean AUC0-48hr above 4 µg/mL with a mean Cmax above 0.5 µg/mL occurring at approximately 3 hours.
Croatian: Primjenom doza prilagođenih veličini površine tijela bolesnicima u dobi od 6 mjeseci do manje od 12 godina postignuta je srednja vrijednost AUC0-48hr iznad 4 µg/ml, uz srednju vrijednost Cmax iznad 0,5 µg/ml koja je nastupila nakon približno 3 sata.
English: 3-day treatment pack containing: 1 x 125 mg hard capsule and 2 x 80 mg hard capsule
Croatian: Pakiranje za trodnevno liječenje sadrži: 1 x 125 mg tvrdu kapsulu i 2 x 80 mg tvrdu kapsulu
English: 2-day treatment pack containing: 2 x 80 mg hard capsule
Croatian: Pakiranje za dvodnevno liječenje sadrži: 2 x 80 mg tvrdu kapsulu
English: The total exposure of orally administered CYP3A4 substrates may increase up to approximately 3-fold during the 3-day treatment with EMEND; the effect of aprepitant on the plasma concentrations of intravenously administered CYP3A4 substrates is expected to be smaller.
Croatian: Ukupna izloženost supstratima CYP3A4 koji se primjenjuju peroralno može se povisti do približno 3 puta tijekom trodnevnog liječenja lijekom EMEND; očekuje se da će utjecaj aprepitanta na koncentraciju u plazmi intravenski primijenjenih supstrata CYP3A4 biti manji.
English: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.
Croatian: Bolesnici s rijetkim nasljednim poremećajima nepodnošenja fruktoze, malapsorpcije glukoze-galaktoze ili nedostatka saharoze-izomaltaze ne smiju uzimati ovaj lijek.
English: Discard all the unused water remaining in the mixing cup.
Croatian: Izlijte svu preostalu vodu iz čaše za miješanje.
English: Complete response: No emesis and no use of rescue Difference (%) calculated as Aprepitant 40 mg minus Ondansetron 4 mg Difference (%) and 95 % C.I.
Croatian: Potpuni odgovor (izostanak povraćanja i bez dodatnih lijekova za olakšanje simptoma) Razlika (%) izračunata kao aprepitant 40 mg minus ondanzetron 4 mg Razlika (%) i 95% CI izračunati pomoću stratificirane Miettinen-Nurminenove metode i Cochran-MantelHaenszelovih težinskih koeficijenata
English: Stop giving this medicine and see a doctor straight away if you or the child notice any of the following serious side effects - the child may need urgent medical treatment: - allergic reaction - the signs may include hives, rash, itching, difficulty breathing or swallowing
Croatian: Prestanite davati ovaj lijek i odmah posjetite liječnika ako Vi ili dijete primijetite bilo koju od sljedećih ozbiljnih nuspojava - dijete bi moglo trebati hitnu medicinsku pomoć: - alergijska reakcija - znakovi mogu uključivati koprivnjaču, osip, svrbež, otežano disanje ili gutanje (nije poznato koliko se često ovo događa).
English: Cmax was 1.6 ± 0.36 µg/mL and 1.4 ± 0.22 µg/mL on Days 1 and 3, respectively.
Croatian: Cmax je iznosio 1,6 ± 0,36 μg/ml 1. dan te 1,4 ± 0,22 μg/ml 3. dan.
English: Eye disorders miosis, visual acuity reduced uncommon
Croatian: Poremećaji oka mioza, smanjena oštrina vida manje često
English: Tell the doctor if you or the child is taking these medicines since the treatment must be modified before you or the child start taking EMEND.
Croatian: Recite liječniku ako Vi ili dijete uzimate ove lijekove jer će morati prilagoditi terapiju prije nego
English: What you need to know before you give EMEND
Croatian: Što morate znati prije nego počnete davati EMEND
English: C]-fosaprepitant, a prodrug for aprepitant, indicating a substantial presence of metabolites in the plasma.
Croatian: radioaktivnosti u plazmi otpada na aprepitant, što ukazuje na znatnu prisutnost njegovih metabolita u plazmi.
English: However, it should be noted that systemic exposure in rodents was similar or even lower than therapeutic exposure in humans at the 125 mg/80 mg dose.
Croatian: Međutim, treba istaknuti da je sistemska izloženost u glodavaca bila slična ili čak niža od terapijske izloženosti u ljudi pri dozi od 125 mg/80 mg.
English: Potassium hydroxide Black iron oxide (E 172)
Croatian: Tinta za označavanje šelak kalijev hidroksid željezov oksid, crni (E 172)
English: Following a single 165 mg aprepitant dose, a transient moderate increase for two days possibly followed by a mild decrease in exposure of immunosuppressants metabolised by CYP3A4 (e.g., cyclosporine, tacrolimus, everolimus and sirolimus) is expected.
Croatian: Nakon jednokratne doze aprepitanta u dozi od 165 mg očekuje se prolazni umjereni porast u trajanju od dva dana, a nakon njega blagi pad izloženosti imunosupresivima koji se metaboliziraju putem CYP3A4 (npr. ciklosporin, takrolimus, everolimus i sirolimus).
English: 80 mg orally
Croatian: 80 mg peroralno
English: • Pour entire contents of the sachet into the 4.6 mL of water and mix.
Croatian: • Istresite cijeli sadržaj vrećice u 4,6 ml vode i promiješajte.
English: Based on a comparable pharmacokinetic/pharmacodynamic profile, the 1-day oral regimen of EMEND 165 mg is anticipated to have a similar safety and tolerability profile to that of the 1-day regimen of fosaprepitant 150 mg and the 3-day oral aprepitant regimen in chemotherapy patients (see section 5.2).
Croatian: Na temelju usporedivih farmakokinetičkih/farmakodinamičkih profila, očekuje se da će jednodnevni režim liječenja lijekom EMEND 165 mg imati sličan sigurnosni profil i profil tolerancije kao i jednodnevni režim liječenja fosaprepitantom od 150 mg i trodnevni režim liječenja aprepitantom u bolesnika na kemoterapiji (vidjeti dio 5.2).
English: As part of a 3-day regimen, dosing of aprepitant powder for oral suspension (3/2/2-mg/kg) in patients aged 6 months to less than12 years achieved an AUC0-24hr above 17 µg•hr/mL on Day 1 with concentrations (Cmin) at the end of Days 2 and 3 above 0.1 µg/mL in a majority of patients.
Croatian: U sklopu trodnevnog režima liječenja, doziranjem aprepitant praška za oralnu suspenziju (3/2/2-mg/kg) u bolesnika u dobi od 6 mjeseci do manje od 12 godina, u većine je bolesnika 1. dana postignut AUC0-24hr iznad 17 µg•hr/ml s koncentracijama (Cmin) na kraju 2. i 3. dana iznad 0,1 µg/ml.
English: EMEND 40 mg should be used with caution in patients receiving pimozide, terfenadine, astemizole, cisapride, or ergot alkaloid derivatives.
Croatian: EMEND 40 mg mora se primjenjivati uz oprez u bolesnika koji se liječe pimozidom, terfenadinom, astemizolom, cisapridom ili derivatima ergot alkaloida.
English: These differences are not considered clinically meaningful.
Croatian: Ove se razlike ne smatraju klinički značajnima.
English: However, in a 9 month study in dogs, no organ weight changes nor gross or histomorphologic findings were present in male reproductive organs at systemic exposures 35-fold above the therapeutic exposure in humans at 40 mg.
Croatian: Međutim, u devetomjesečnom ispitivanju na psima, pri sustavnoj izloženosti 35 puta većoj od terapijske izloženosti u ljudi pri dozi od 40 mg, nisu zabilježene promjene težine organa kao niti makroskopske ni histomorfološke promjene muških reproduktivnih organa.
English: Skin and subcutaneous tissue disorders pruritus, rash, urticaria, Stevens-Johnson syndrome/toxic epidermal necrolysis not known
Croatian: Poremećaji kože i potkožnog tkiva pruritus, osip, urtikarija, Stevens-Johnsonov sindrom/toksična epidermalna nekroliza nepoznato
English: In patients with severe renal impairment, the AUC0- of total aprepitant (unbound and protein bound) decreased by 21 % and Cmax decreased by 32 %, relative to healthy subjects.
Croatian: U bolesnika s teškim oštećenjem funkcije bubrega AUC0-∞ ukupnog aprepitanta (slobodnog i vezanog na proteine) snizio se za 21%, a Cmax za 32% u odnosu na zdrave ispitanike.
English: EMEND is given for 3 days as part of a regimen that includes a 5-HT3 antagonist.
Croatian: EMEND se primjenjuje 3 dana u sklopu režima liječenja koji uključuje antagonist 5-HT3.
English: Inhibition of cytochrome P450 isoenzyme 3A4 (CYP3A4) by aprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious adverse reactions (see section 4.5).
Croatian: Inhibicija izoenzima 3A4 (CYP3A4) citokroma P450 aprepitantom može dovesti do povišenja koncentracije tih lijekova u plazmi, što može izazvati ozbiljne nuspojave (vidjeti dio 4.5).
English: The effect may be maintained for a few days, and is expected to be clinically insignificant by two weeks after the end of treatment with EMEND.
Croatian: Ovaj učinak može trajati nekoliko dana te se očekuje da padne ispod klinički značajne razine dva tjedna nakon završetka liječenja lijekom EMEND.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING (INCLUDING 2 HARD CAPSULES 80 MG)
Croatian: PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU (PAKIRANJE S 2 TVRDE KAPSULE PO 80 mg)
English: EMEND (40 mg) should be used with caution in patients receiving concomitant administration of pimozide, terfenadine, astemizole, cisapride or ergot alkaloid derivatives.
Croatian: EMEND (40 mg) se mora primjenjivati uz oprez u bolesnika koji istodobno primaju pimozid, terfenadin, astemizol, cisaprid ili derivate ergot alkaloida.
English: The AUC of orally administrated midazolam increased by 1.2-fold when a single dose of 40 mg aprepitant was co-administered with a single oral dose of 2 mg midazolam; this effect was not considered clinically important.
Croatian: Nakon primjene jednokratne doze peroralnog aprepitanta s jednokratnom dozom peroralnog midazolama od 2 mg, AUC midazolama u plazmi porastao je 1,2 puta; ovo se učinci nisu smatrali klinički važnim.
English: However, it should be noted that systemic exposure in rodents was similar or even lower than therapeutic exposure in humans at the 125 mg/80 mg and 165 mg doses.
Croatian: Treba, međutim, istaknuti da je sistemska izloženost glodavaca bila slična ili čak niža od terapijske izloženosti u ljudi pri dozama od 125 mg/80 mg i 165 mg.
English: Stop taking EMEND and see a doctor immediately if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment: - Hives, rash, itching, difficulty breathing or swallowing (frequency not known, cannot be estimated from the available data); these are signs of an allergic reaction.
Croatian: Prestanite uzimati EMEND i odmah posjetite liječnika ako primjetite bilo koju od sljedećih nuspojava, koje bi mogle biti ozbiljne, i za koje ćete možda trebati hitnu medicinsku pomoć: - Koprivnjača, osip, svrbež, otežano disanje ili gutanje (učestalost nije poznata, ne može se procijeniti iz dostupnih podataka); ovo su znakovi alergijske reakcije.
English: Standard therapy (N= 524)
Croatian: Standardna terapija (N= 524)
English: Acute phase: 0 to 24 hours following initiation of chemotherapy.
Croatian: Akutna faza: od 0 do 24 sata nakon početka kemoterapije.
English: For CYP2C9 and CYP3A4 substrates, the induction is transient with a maximum effect reached 3-5 days after end of the EMEND 3-day treatment.
Croatian: Za supstrate CYP2C9 i CYP3A4 indukcija je prolazna, s najsnažnijim učinkom 35 dana nakon završetka trodnevnog liječenja lijekom EMEND.
English: In clinical interaction studies, aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg on Days 2 and 3, did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron).
Croatian: U kliničkim ispitivanjima interakcija lijekova, aprepitant primijenjen kao režim liječenja od 125 mg 1. dan i 80 mg 2. i 3. dan liječenja, nije imao klinički važne učinke na farmakokinetiku ondanzetrona, granizetrona niti hidrodolazetrona (aktivnog metabolita dolazetrona).
English: The powder for oral suspension is used in children aged 6 months to less than 12 years in combination with other medicines to prevent nausea and vomiting caused by chemotherapy (cancer treatment) that are strong and moderate triggers of nausea and vomiting (such as cisplatin, cyclophosphamide, doxorubicin or epirubicin).
Croatian: Prašak za oralnu suspenziju primjenjuje se u djece u dobi od 6 mjeseci do manje od 12 godina u kombinaciji s drugim lijekovima za sprječavanje mučnine i povraćanja uzrokovanih kemoterapijom (liječenjem raka) koja je jaki ili umjereni okidač mučnine i povraćanja (na primjer, cisplatin, ciklofosfamid, doksorubicin ili epirubicin).
English: The aprepitant regimen for adolescents aged 12 through 17 years (n=47) consisted of EMEND capsules 125 mg orally on Day 1 and 80 mg/day on Days 2 and 3 in combination with ondansetron on Day 1.
Croatian: Režim liječenja aprepitantom za adolescente u dobi od 12 do 17 godina (n=47) sastojao se od EMEND kapsula 125 mg peroralno 1. dana i 80 mg na dan 2. i 3. dana u kombinaciji s ondanzetronom 1. dana.
English: Aprepitant regimen (N= 425)
Croatian: Režim s aprepitantom (N= 425)
English: Aluminium blister containing one 125 mg capsule and two 80 mg capsules.
Croatian: Aluminijski blister s jednom kapsulom od 125 mg i dvije kapsule od 80 mg.
English: No emesis (no emetic episodes regardless of use of rescue therapy) Overall (0-120 hours)
Croatian: Bez povraćanja (izostanak povraćanja bez obzira na primjenu dodatnih lijekova) Ukupno (0-120 sati)
English: Do not take EMEND: - if you are allergic to aprepitant or any of the other ingredients of this medicine (listed in section 6).
Croatian: Nemojte uzimati EMEND: - ako ste alergični na aprepitant ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: EMEND is used in adults in combination with other medicines to prevent nausea and vomiting caused by chemotherapy (cancer treatment) containing cisplatin (a strong trigger of nausea and vomiting) and with chemotherapy that is a moderate trigger of nausea and vomiting (such as cyclophosphamide, doxorubicin or epirubicin).
Croatian: EMEND se koristi u odraslih bolesnika u kombinaciji s drugim lijekovima za sprječavanje mučnine i povraćanja uzrokovanih kemoterapijom (lijekovima za liječenje raka) koja sadrži cisplatin (jaki okidač mučnine i povraćanja) i kemoterapijom koja je umjereni okidač mučnine i povraćanja (kao što su ciklofosfamid, doksorubicin ili epirubicin).
English: Please talk to the doctor or pharmacist if you or the child is taking any of the following medicines:
Croatian: Obavijestite liječnika ili ljekarnika ako Vi ili dijete uzimate bilo koji od sljedećih lijekova:
English: Do not take EMEND: - if you or the child is allergic to aprepitant or any of the other ingredients of this medicine (listed in section 6).
Croatian: Nemojte uzimati EMEND: - ako ste Vi ili dijete alergični na aprepitant ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: The oral suspension should be prepared and the dose measured by healthcare professionals only.
Croatian: Samo zdravstveni radnik smije pripremiti oralnu suspenziju i odmjeriti dozu.
English: Paediatric population: As part of a 3-day regimen, dosing of aprepitant capsules (125/80/80-mg) in adolescent patients (aged 12 through 17 years) achieved an AUC0-24hr above 17 µg•hr/mL on Day 1 with concentrations (Cmin) at the end of Days 2 and 3 above 0.4 µg/mL in a majority of patients.
Croatian: Pedijatrijska populacija: Primjenom kapsula aprepitanta (125/80/80-mg) kao trodnevnog režima liječenja u adolescentnih bolesnika (u dobi od 12 do 17 godina), u većine je bolesnika 1. dana postignut AUC0-24hr iznad 17 µg•hr/ml s koncentracijama (Cmin) na kraju 2. i 3. dana iznad 0,4 µg/ml.
English: Standard therapy (N= 424)
Croatian: Standardna terapija (N= 424)
English: Aprepitant is a substrate, a moderate inhibitor, and an inducer of CYP3A4.
Croatian: Aprepitant je supstrat, umjereni inhibitor, ali i induktor izoenzima CYP3A4.
English: Oral administration of the capsule with a standard light breakfast and a high-fat breakfast resulted in an up to an 8 % and a 47 % increase in AUC0-∞ of aprepitant, respectively.
Croatian: Peroralna primjena kapsula uz standardni lagani doručak povisila je AUC0-∞ aprepitanta za 8%, dok je primjena kaspula uz doručak bogat masnoćama povisila AUC0-∞ aprepitanta za 47 %.
English: Efficacy was based on evaluation of the following composite measures: complete response in both the overall and delayed phases and no vomiting in the overall phase.
Croatian: Ocjena djelotvornosti zasnivala se na sljedećim skupnim mjerama učinka: potpunom odgovoru na liječenje tijekom cijelog razdoblja i u kasnijoj fazi te izostanku povraćanja tijekom cijelog razdoblja.
English: A single dose of aprepitant 200 mg on Day 1 co-administered with midazolam, a sensitive CYP3A4 substrate, on Days 1, 4 and 8 resulted in a 35 % reduction of midazolam AUC0-∞ on Day 8.
Croatian: Istodobna primjena jednokratne doze aprepitanta u dozi od 200 mg 1. dan liječenja i midazolama, osjetljivog supstrata CYP3A4, 1., 4. i 8. dan liječenja snizila je AUC0-∞ midazolama 35% 8. dan liječenja.
English: What you need to know before you take EMEND
Croatian: Što morate znati prije nego počnete uzimati EMEND
English: The efficacy of the aprepitant regimen was apparently maintained during all cycles.
Croatian: U svim je ciklusima režim liječenja aprepitantom održao djelotvornost.
English: * The confidence intervals were calculated with no adjustment for gender and concomitant chemotherapy, which were included in the primary analysis of odds ratios and logistic models.
Croatian: * Intervali pouzdanosti izračunati su bez prilagođavanja prema spolu i istodobnoj kemoterapiji, koji su obuhvaćeni primarnom analizom omjera šansi i logističkih modela.
English: Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy in adults.
Croatian: Prevencija akutne i odgođene mučnine i povraćanja povezanih s izrazito emetogenom kemoterapijom raka zasnovanom na cisplatinu u odraslih.
English: Each pack of EMEND contains a sachet with the powder for oral suspension, a 1 ml and a 5 ml oral dispenser, one cap and one mixing cup.
Croatian: Jedno pakiranje lijeka EMEND sadrži vrećicu s praškom za oralnu suspenziju, oralni dozator od 1 ml i 5 ml, jedan poklopac i jednu čašu za miješanje.
English: The recommended oral dose of EMEND is one 40 mg capsule within 3 hours prior to the start of anaesthesia.
Croatian: Preporučena doza lijeka EMEND je jedna kapsula od 40 mg primijenjena kroz usta unutar 3 sata prije početka anestezije.
English: Your doctor will ask you to continue taking other medicines including a corticosteroid (such as dexamethasone) and a ‘5HT3 antagonist' (such as ondansetron) for preventing nausea and vomiting the following three days.
Croatian: Nakon liječenja lijekom EMEND, Vaš će Vam liječnik preporučiti uzimanje drugih lijekova uključujući kortikosteroide (kao što je deksametazon) i „5-HT3 antagoniste“ (kao što je odnanzetron) za sprječavanje mučnine i povraćanja slijedeća tri dana.
English: EMEND can be taken with or without food.
Croatian: EMEND se može uzimati sa ili bez hrane.
English: Other side effects Tell the doctor, pharmacist or nurse if you or the child notice any of the following side effects:
Croatian: Obavijestite liječnika, ljekarnika ili medicinsku sestru ako Vi ili dijete primijetite bilo koju od sljedećih nuspojava:
English: Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1.
Croatian: Deksametazon treba primijeniti 1. dan liječenja 30 minuta prije kemoterapije.
English: The recommended oral dose of EMEND is one 165 mg capsule on the first day of your chemotherapy treatment cycle.
Croatian: Preporučena peroralna doza lijeka EMEND je jedna kapsula od 165 mg 1 sat prije početka kemoterapije 1. dana kemoterapije.
English: Excipient with known effect Each capsule contains 165 mg of sucrose.
Croatian: Pomoćna tvar s poznatim učinkom Jedna kapsula sadrži 165 mg saharoze.
English: In patients on chronic warfarin therapy, the prothrombin time (INR) should be monitored closely during treatment and for 14 days following the use of EMEND 165 mg for chemotherapy induced nausea and vomiting (see section 4.4).
Croatian: U bolesnika na kroničnom liječenju varfarinom protrombinsko vrijeme (INR) treba strogo nadzirati za vrijeme liječenja lijekom EMEND te tijekom 14 dana nakon primjene lijeka EMEND 165 mg za prevenciju mučnine i povraćanja izazvanih kemoterapijom (vidjeti dio 4.4).
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING (INCLUDING 1 HARD CAPSULE 125 MG AND 2 HARD CAPUSULES 80 MG)
Croatian: PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU (PAKIRANJE S 1 TVRDOM KAPSULOM OD 125 mg I 2 TVRDE KAPSULE OD 80 mg)
English: In a second multicentre, randomised, double-blind, parallel-group, clinical study, the aprepitant regimen was compared with standard therapy in 848 adult patients (652 females, 196 males) receiving a chemotherapy regimen that included any intravenous dose of oxaliplatin, carboplatin, epirubicin, idarubicin, ifosfamide, irinotecan, daunorubicin, doxorubicin; cyclophosphamide intravenously (< 1,500 mg/m2); or cytarabine intravenously (> 1 g/m2).
Croatian: U drugom multicentričnom, randomiziranom, dvostruko slijepom kliničkom ispitivanju s paralelnim skupinama, režim liječenja aprepitantom uspoređen je sa standardnom terapijom u 848 odrasih bolesnika (652 žene, 196 muškaraca) koji su primali kemoterapiju koja je obuhvaćala intravensku primjenu bilo koje doze oksaliplatina, karboplatina, epirubicina, idarubicina, ifosfamida, irinotekana, daunorubicina, doksorubicina; intravenski ciklofosfamid (<1500 mg/m2); ili intravenski citarabin
English: Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.
Croatian: Prevencija mučnine i povraćanja povezanih s umjereno emetogenom kemoterapijom raka u odraslih.
English: Each carton contains one sachet with the powder for oral suspension, one 1 ml and one 5 mL oral dispenser (polypropylene with silicone o-ring), one cap, and one mixing cup (polypropylene).
Croatian: Jedna kutija sadrži jednu vrećicu s praškom za oralnu suspenziju, jedan oralni dozator od 1 ml i jedan od 5 ml (polipropilenski, sa silikonskim o-prstenom), jedan poklopac i jednu čašu za miješanje (polipropilensku).
English: During continuous treatment with methylprednisolone, the AUC of methylprednisolone may decrease at later time points within 14 days following initiation of the EMEND dose, due to the inducing effect of aprepitant on CYP3A4.
Croatian: Nastavi li se liječenje metilprednizolonom, AUC metilprednizolona može se smanjiti unutar 14 dana od početka primjene lijeka EMEND jer aprepitant djeluje i kao induktor CYP3A4.
English: If you or the child have been told by your doctor that you or the child have an intolerance to some sugars, contact the doctor before taking this medicine.
Croatian: Ako Vam je liječnik rekao da Vi ili dijete ne podnosite neke šećere, savjetujte se s liječnikom prije uzimanja ovog lijeka.